Cytochrome P450 1A2 phenotyping for student laboratories

Authors

  • Sandra Priller Institute of Pharmacy and Food Chemistry, Julius-Maximilians-Universitat Wurzburg, Am Hubland, D-97074, Wurzburg,Germany.
  • Matthias Unger Institute of Pharmacy and Food Chemistry, Julius-Maximilians-Universitat Wurzburg, Am Hubland, D-97074, Wurzburg,Germany
  • Ulrike Holzgrabe Institut fur Pharmazie und Lebensmittelchemie, Am Hubland, D-97074, Wurzburg, Germany,

Keywords:

Clinical Pharmacy, CYP1A2, cytochrome P450, HPLC, phenotyping, laboratory teaching

Abstract

The purpose of this research is to impart basic knowledge about the cytochrome P450 metabolism of xenobiotics and its meaning for pharmaceutical and medical problems by means of experiment-led learning. The teaching approach includes anexperimental part and bibliographic investigations as well as a discussion of the obtained results. The experimental work describes two simple methods for phenotyping cytochrome P450 1A2 in humans by HPLC – UV measurement of caffeine and its main metabolite paraxanthine in urine and saliva.These simple and inexpensive methods are applicable to demonstrate the importance of cytochrome P450 enzymes concerning drug inefficacy, drug– drug interactions and adverse drug reactions. Two simple and fast HPLC – UV methods for phenotyping cytochrome P450 1A2 in humans are presented. Using these methods, probands can be classified into poor and fast metabolisers by the determination of the paraxanthine/caffeine ratio in saliva and urine. Since our HPLC methods are inexpensive and simple to carry out, the experiments are particularly suitable for pharmaceutical and medical student laboratories. 

References

Bendriss E., Markoglou N. and Wainer I.W. (2000). Liquid chromatographic method for the simultaneous determination of caffeine metabolites in urine. Journal of Chromatography B,746, 331-338

Berthold H. . (1999)., Klinikleitfaden Arzneimitteltherapie, 2.2 – 2.3, 75-89, Urban & Fischer-Verlag, München, Jena, Germany.

Brüggmann J. . (2003). Arzneimittelinteraktionen in Jaehde U., Mühlebach S., Radziwill R., Schunack W. . (eds.), Lehrbuch der klinischen Pharmazie, 2. . neubearb. . u. . erw. . Aufl., Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany, 15, 225-240.

Carillo J.A. . and Benitez J. . (1994). Caffeine metabolism in a healthy Spanish population: N-Acetylator phenotype and oxidation pathways. . Clinical Pharmacology and Therapeutics, 55, 293-304

Carillo J.A. . and Benitez J. . (1996). CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. . British Journal of Clinical Pharmacology, 41:, 605-608

Carillo J.A., Christensen M., Ramos S.I., Alm C.; Dahl M.L.; Benitez J. . and Bertilsson L. . (2000). Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. . Therapeutic Drug Monitoring, 22, 409-417

Crews H.M., Olivier L. . and Wilson L.A. . (2001). Urinary biomarkers for assessing dietary exposure to caffeine. . Food Additives and Concomitants, 18, 1075-1087

Forsyth J.T., Grünewald R.A., Rostami-Hodjegan R.A., Lennard M.S., Sagar H.J and Tucker G.T. (2000). Parkinson’s disease and CYP1A2 activity. British Journal of Clinical Pharmacology, 50,: 303- 309.

Fuhr U.and Rost K.L. . ((1994). Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics,:4:, 109 –116.

Fuhr U., Rost K.L., Engelhardt R., Sachs M., Liermann D., Belloc C., Beaune P., Janezic S., Grant D., Meyer U.A. . and Staib A.H. . (1996). Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics, 6: 159.

Guidance for Industry-Bioanalytical Method validation (May 2001), U.S. Department of Health and Human Services, FDA, U.S.A.

Holland D., Godfredsen K.A., Page T. . and Connor J.D. . (1998). Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation. Journal of Chromatography B, 707, 105-110.

Kalow W. . and Tang B. . (1993). The use of caffeine for enzyme assays: A critical appraisal. . Clinical Pharmacology and Therapeutics, 53, 503-514

Kaddlubar F.F., Talaska G., Butler, M.A., Teitel C.H., Massengill J.P. . and Lang N.P. . (1990). Determination of carcinogenic arylamine N-Oxidation phenotype in humans by analysis of caffeine urinary metabolites. . In Mendelsohn M.L. . and Albertini R.J. . (eds) Mutation and the Environment, Part B: Metabolism, Testing Methods and Chromosomes, John Wiley, New York, NY, 107-114.

Kalow, W., & Tang, B. (1993). The use of caffeine for enzyme assays: A critical appraisal.Clinical Pharmacology and Thera-peutics,53, 503– 514.

Koch, J. P., ten Tusscher, G. W., Koppe, J. G., & Guchelaar, H. J.(1999). Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. Biomedical Chromatography,13, 309–314.

Lampe, J. W., King, I. B., Li, S., Grate, M. T., Barale, K. V.,Chen, C., Feng, Z., & Potter, J. D. (2000). Brassica vegetables and apiaceous vegetables decrease cytochromeP450 1A2 activity in humans: Changes in caffeine metaboliteratios in response to controlled vegetable diets.Carcinogenesis,21(6), 1157–1162.

Licinio, J., & Wong, M. (2002).Pharmacogenomics—The search forindividualized therapies. Weinheim, Germany: Wiley-VCH VerlagGmbH, 1– 2, 1 –34.

McQuilkin, S. H., Nierenberg, D. W., & Bresnick, E. (1995).Analysis of within-subject variation of Caffeine metabolism when used to determine cytochrome P450 1A2 and N-Acetyltransferase-2 activities.Cancer Epidemiology, Biomarkers& Prevention,4, 139–146.

Minors, J. O., Coulter, S., Tukey, R. H., Veronese, M. E., & Birkett,D. J. (1996). Cytochromes P450, 1A2, and 2C9 are responsiblefor the human hepatic O-demethylation of R- and S-naproxen.Biochemical Pharmacology,51, 1003–1008.

Newton, R., Broughton, L. J., Lind, M. J., Morrison, P. J., Rogers,H. J., & Bradbrook, I. D. (1981). Plasma and salivary pharmacokinetics of caffeine in man. European Journal of Clinical Pharmacology,21, 45–52.

Nyeki, A., Biollaz, J., Kesselring, U. W., & Decosterd, L. A. (2001).Extractionless method for the high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthineoxidase activity assessment.Journal of Chromatography B,755,73–84.

Raucy, J. L., Lasker, J. M., Lieber, C. S., & Black, M (1989).Acetaminophen activation by human liver cytochromesP450IIE1 and P450IA2. Archives of Biochemistry and Biophysics,271, 270 –283.

Schrenk, D., Brockmeier, D., Mo ̈ rike, K., Bock, K. W., &Eichelbaum, M. (1998). A distribution study of CYP1A2phenotypes among smokers and non-smokers in a cohort ofhealthy Caucasian volunteers.European Journal of Clinical Pharmacology,53, 361–367.

Sinues, B., Sa ́enz, M. A., Lanuza, J., Bernal, M. L., Fanlo, A., Juste,J., & Mayayo, E. (1999). Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relation-ships with urinary mutagenicity and urine flow.Cancer Epidemiology, Biomarkers & Prevention,8, 159–166.

Spigset, O., Hagg, S., Soderstrom, E., & Dahlquist, R. (1999). Theparaxanthine: caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: When should the sample be obtained?Pharmacogenetics,9, 409– 412.

Stockley, I. H. (2001).Drug Interactions. Vol. 1. 5th ed. (pp. 1–15). London, UK: Pharmaceutical Press.

Tancheva-Poor, I., Zaigler, M., Rietbrock, S., & Fuhr, U. (1999).Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.Pharmacogenetics,9, 131 –144

Downloads

Published

2018-08-18

How to Cite

Priller, S., Unger, M., & Holzgrabe, U. (2018). Cytochrome P450 1A2 phenotyping for student laboratories. Pharmacy Education, 5(2). Retrieved from https://pharmacyeducation.fip.org/pharmacyeducation/article/view/156

Issue

Section

Research Article